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A B S T R A C T
Background
Cystic fibrosis is the most common life-limiting autosomal recessive genetic disorder in white populations. Distal intestinal obstruction
syndrome (DIOS) is an important morbidity in cystic fibrosis. It is the result of the accumulation of viscid faecal material within
the bowel which combines with thick, sticky mucus produced in the intestines of people with cystic fibrosis. The intestine may be
completely blocked (complete DIOS) or only partially blocked (incomplete DIOS). Once a diagnosis of DIOS has been made, the goal
of therapy is to relieve the acute complete or incomplete faecal obstruction and ultimately prevent the need for surgical intervention.
Objectives
This review aimed to evaluate the effectiveness and safety of different treatment regimens for the treatment of DIOS (complete and
incomplete) in children and adults with cystic fibrosis.
Search methods
We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and handsearching of journals
and conference abstract books. We also searched the reference lists of relevant articles and reviews.
Date of last search: 24 July 2018.
We also searched the following trials registries and other resources: ClinicalTrials.gov; International Standard Randomised Controlled
Trial Number (ISRCTN) Registry; the WHO International Clinical Trials Registry; and Open Grey.
Date of last searches: 10 June 2018.
Selection criteria
Randomised controlled trials, quasi-randomised controlled trials (including cross-over trials (to be judged on an individual basis))
comparing the use of laxative agents or surgery for treating DIOS in children, young people and adults with cystic fibrosis to each
other, placebo or no intervention.
Data collection and analysis
Two authors independently screened papers, extracted trial details and assessed for risk of bias. The authors assessed the quality of
evidence using GRADE.
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Main results
There was one trial with 20 participants (16 females) included in the review. The mean age of participants was 13.1 years. The trial
was a double-blinded, randomised cross-over trial which had a duration of 12 months in total and compared high-dose and low-dose
pancreatic enzyme therapy. As only the abstract of the trial was available, the overall risk of bias was judged to be unclear. The trial
did not address either of our primary outcomes (time until resolution of DIOS and treatment failure rate), but reported episodes of
acute DIOS, presence of abdominal mass and abdominal pain. There were no numerical data available for these outcomes, but the
authors stated that there was no difference between treatment with high-dose or low-dose pancreatic enzymes. The overall quality of
the evidence was found to be very low.
Authors’ conclusions
There is a clear lack of evidence for the treatment of DIOS in people with cystic fibrosis. The included abstract did not address our
primary outcome measures and did not provide numerical data for the two secondary outcomes it did address. Therefore, we cannot
justify the use of high-dose pancreatic enzymes for treating DIOS, nor can we comment on the efficacy and safety of other laxative
agents. From our findings, it is clear that more randomised controlled trials need to be conducted in this area.
P L A I N L A N G U A G E S U M M A R Y
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Review question
We reviewed the evidence about the effectiveness and safety of different treatments for distal intestinal obstruction syndrome (DIOS)
in children and adults with cystic fibrosis.
Background
Cystic fibrosis is a common, life-limiting, inherited disease. One of the main features of cystic fibrosis is the thick, sticky mucus
produced by many organs including the lungs, pancreas and intestine. DIOS occurs when mucus in the intestine combines with faeces
and builds up to produce a mass. This mass can partially or completely block the intestine and cause symptoms such as vomiting, severe
abdominal pain and a swollen stomach (abdominal distension). Once a diagnosis of DIOS has been made, the goal of therapy is to
relieve the complete or partial blockage and ultimately prevent the need for any surgical intervention.
Search date
The evidence is current to: 10 June 2018.
Trial characteristics
The review included one trial with 20 people with cystic fibrosis who were aged between 7.1 and 23.2 years of age (average 13.1 years
old). The 12-month trial compared a high dose of pancreatic enzymes with a low dose of pancreatic enzymes for treating chronic DIOS.
Key results
The trial did not report on our primary outcomes (time until DIOS successfully treated and treatment failure rate), but addressed
two of our secondary outcomes; episodes of acute DIOS and the harmful effects that might occur in participants (the presence of an
abdominal mass and abdominal pain). There were no numerical data available for these results, but the authors reported that there was
no difference between high-dose or low-dose pancreatic enzymes.
Quality of the evidence
We found the overall quality of the evidence to be very low. The trial itself was only published as an abstract from a conference which
did not include numerical data and it was not published as a full report. This meant that we do not know many details about the trial.
We thought that the overall risk of bias was unclear, as the trial authors did not describe how participants were put into the treatment
groups, whether any participants dropped out or whether the planned outcomes were the same as the reported outcomes. The trial
also had a very small number of participants and a limited age range, making it difficult to draw conclusions about the relevance of the
treatment for all people with cystic fibrosis.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
High-dose pancreatic enzymes compared with low-dose pancreatic enzymes for treating DIOS
Patient or population: children and adults with cyst ic f ibrosis
Settings: outpat ient
Intervention: high-dose pancreat ic enzymes
Comparison: low-dose pancreat ic enzymes
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(trials)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Low-dose pancreatic
enzymes
High-dose pancreatic
enzymes
Time taken from start
of treatment until the
resolution of DIOS
Outcome not reported. N/ A
Treatment failure rate Outcome not reported. N/ A
Adherence Outcome not reported. N/ A
Episodes of acute DIOS
Follow-up: at 12 months
There was no dif ference between low-dose and
high-dose pancreat ic enzymes
N/ A 20
(1 trial)
⊕©©©
very lowa,b,c,d,e,f
Adverse effects: ab-
dominal mass
Follow-up: at 12 months
There was no dif ference between low-dose and
high-dose pancreat ic enzymes
N/ A 20
(1 trial)
⊕©©©
very lowb,c,d,e,f
Adverse effects: ab-
dominal pain
Follow-up: at 12 months
There was no dif ference between low-dose and
high-dose pancreat ic enzymes
N/ A 20
(1 trial)
⊕©©©
very lowb,c,d,e,f
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; DIOS: distal intest inal obstruct ion syndrome; N/A: not applicable.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
a The method of measurement of episodes of acute DIOS (e.g. numbers, %, per person or total number of episodes) was not
described in the trial.
b The small number of part icipants in the trial (20) decreases the precision of the results.
c The part icipants had a very lim ited age range (7.1 years to 23.2 years), making the evidence for these outcomes restricted
to this group, and therefore increasing its indirectness.
d The majority of the risk of bias domains were ranked as unclear (select ion bias, attrit ion bias and report ing bias) as there
was lit t le information provided in the trial.
eNo specif ic numerical data were provided for the results of these outcomes, therefore we cannot be sure of the signif icance
or relevance of these results.
f There was no washout period described in this cross-over trial, therefore we cannot be sure whether there was a carry-over
ef fect of the treatments.
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B A C K G R O U N D
Please see the appendices for a glossary of terms used in the review
(Appendix 1). For definitions of Cochrane statistical and method-
ological terms, please see the Cochrane Community Glossary.
Description of the condition
Cystic fibrosis (CF) is the most common life-limiting autosomal
recessive genetic disorder in white populations. An affected indi-
vidual must possess two defective copies of the gene that encodes a
protein called the cystic fibrosis transmembrane conductance reg-
ulator (CFTR). Approximately 1 in 25 of the UK white popula-
tion carry a single defective copy of this gene, and 1 in 2500 new-
borns in the UK are born with CF (Tobias 2011). Worldwide, CF
affects approximately 70,000 children and adults (Cystic Fibrosis
Foundation Patient Registry 2012).
Although respiratory symptoms are most prominent and often the
focus of clinical care, CF also has important effects on the gas-
trointestinal and endocrine systems. The CFTR protein translates
into an ion channel responsible for conducting negatively charged
ions (notably chloride, bicarbonate and thiocyanate ions) across
various cell membranes in the body, and thus indirectly influences
water transport across these membranes. Absent or dysfunctional
CFTR leads to thickened, dehydratedmucus. Affected individuals
experience multi-organ dysfunction, resulting in morbidity and
reduced quality of life.
Distal intestinal obstruction syndrome (DIOS) is an important
morbidity in CF. It occurs when the thick, faecal material com-
bines with sticky mucus in the CF intestine, commonly in the ter-
minal ileum and caecum, making it fixed in position and difficult
to remove (Colombo 2011). This may cause complete blockage
(complete DIOS) or partial blockage (incomplete DIOS).
DIOS affects between 10% to 22% of individuals with CF
(Davidson 1987; Dray 2004); and is associated with meconium
ileus, liver disease, diabetes mellitus and Pseudomonas aeruginosa
infection (Munck 2016). It also occurs in individuals who have
pancreatic enzyme deficiency and, anecdotally, in those who do
not adhere to pancreatic enzyme replacement therapy (Hess 2015).
Distinguishing DIOS from other causes of bowel
obstruction in CF
The CF gut is prone to obstruction from other causes due to
its altered pathophysiology. A small but significant proportion of
newbornswithCFpresent either at birth or shortly afterwardswith
a type of bowel obstruction called meconium ileus. Meconium
ileus occurs in 13% to 17% of all people with CF (Van der Doef
2011). Throughout life, children and adults with CF are prone
to constipation, with almost half of all children studied (47%)
having evidence of constipation (Van der Doef 2011).
However, it is possible to distinguish between constipation and
DIOS clinically and radiologically. DIOS is an acute complete or
incomplete faecal obstruction in the ileocecum, whereas consti-
pation is defined as gradual faecal impaction of the total colon
(Houwen 2010). A further important differential diagnosis that
needs to be considered in individuals with suspected DIOS is ob-
struction caused by scar tissue (adhesions) from previous abdom-
inal surgery.
Description of the intervention
Once a diagnosis of DIOS has been made, the goal of therapy is
to relieve the acute complete or incomplete faecal obstruction and
ultimately prevent the need for surgical intervention. A number
of medical treatments are used for managing DIOS.
Osmotic laxatives
Osmotic laxatives are faecal softeners which work by increasing
water in the large bowel, either by drawing fluid from body into
bowel or by retaining fluid they were administered with.
Lactulose
Lactulose is an oral osmotic laxative which is widely used, but
may cause flatulence or abdominal pain in high doses (Colombo
2011).
Macrogol 3350
Macrogol 3350 is recommended as first-line treatment for consti-
pation in children and adults (NICE 2015). Maintenance treat-
ment with the oral powders (e.g. Movicol®) are given to children
with chronic constipation. Intensive treatment courses may be
necessary for cases of faecal impaction (BNF 2016; BNFc 2016).
Macrogol 3350 can also be formulated as a bowel cleansing prepa-
ration (e.g. Klean-Prep®). This solution is administered until clear
fluid is passed per rectum. As large volumes are required, it is of-
ten necessary to administer via nasogastric tube or gastrostomy
(Colombo 2011; NICE 2015).
Diatrizoate
Oral diatrizoate (known under the brand name Gastrografin®)
is used by many centres to treat DIOS. It is given as a single
dose, which can be repeated after 24 hours. Rectal diatrizoate can
also be used in more severe cases (Colombo 2011). As diatrizoate
is highly osmotic, the individual must be adequately hydrated
prior to administration in order to avoid complications such as
hypovolemia (a decrease of the volume of circulating blood) and
perforation of the bowel (Tuladhar 1999).
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Stimulant laxatives
Stimulant laxatives work by increasing intestinal motility and re-
ducing gut transit time. They stimulate peristalsis by enhancing
muscle contraction of the bowel wall. A common side effect in-
cludes abdominal cramp and prolonged use may cause diarrhoea
and a loss of electrolytes (notably potassium ions) in the stools
(BNF 2016).
Senna
Senna acts by stimulating peristalsis and increases emptying of the
bowel. Senna is therefore useful when the individual has soft stools
but find it difficult to pass them (NICE 2015).
Sodium docusate
Sodium docusate acts both as a stimulant and also as a stool soft-
ener. It can be administered orally, but if this does not relieve faecal
impaction, the drug can also be given as an enema (NICE 2015).
Sodium picosulphate
Sodium picosulphate acts by stimulating the mucosa of the large
bowel, increasing its motility. It is given as an oral solution (BNF
2016; BNFc 2016).
Mucolytics
Mucolytics work by breaking down the thick, viscid mucus pro-
duced in CF, so may be useful at disintegrating the mucofaeculant
material that is adhered to the bowel wall in DIOS.
Oral N-acetylcysteine
N-acetylcysteine (known under the brand name Parvolex®) is
indicated for abnormal or impaired mucus production. It can be
given as a single oral dose for treatment of meconium ileus or
DIOS. It is typically diluted in a sweeter drink such as orange juice
or cola to mask the strong and bitter taste (BNFc 2016).
Other agents
In addition to laxative agents, other interventions may also be
used to treatDIOS. These include prokinetic drugs, e.g.macrolide
antibiotics, metoclopramide, cisapride that help to increase gas-
trointestinal motility (Longo 1993). Increasing the dose of pan-
creatic enzyme replacement therapy may also improve symptoms
of DIOS, as optimum usage has been shown to prevent further
episodes (Colombo 2011).
Surgery
Surgical decompression of DIOS is reserved for the most refrac-
tory cases not responding to medical management. This interven-
tion is associated with high post-operative morbidity and is there-
fore used as a last resort (Docherty 1992; Rescorla 1993). Other
surgical techniques are described in the literature, e.g. caecostomy,
right hemicolectomy and small bowel resection, but these are as-
sociated with bleeding, delayed healing of wounds and postoper-
ative infection. In turn, these factors increase the risk of mortality
in surgery (Hodson 1976; Lavie 2015).
How the intervention might work
The aim of DIOS treatment is to clear the luminal contents of
the bowel and prevent complete obstruction. Different treatment
regimens have different mechanisms of action. The simple laxa-
tives can be broadly characterised as osmotic laxatives, stimulant
laxatives and mucolytics. Some agents have more than one mech-
anism of action, e.g. macrogol 3350, which is both a stool softener
and a stimulant. Diatriozate is a potent osmotic agent and works
by drawing fluid into the bowel to soften the inspissated faecal
material. N-acetyl-cysteine is a mucolytic agent, and is likely to
work by breaking down themucoid content of the intestinal mass.
Why it is important to do this review
For people with CF, DIOS is a common complication (Van der
Doef 2011). If medical treatment fails and surgery is required,
this is likely to increase the risks to the person with CF (Hodson
2007). Currently, there is variation in practice between centres and
individual doctors and much of this variation is driven by anec-
dotal evidence and local experience. Identifying the best medical
treatment strategy will enable clinicians to make better informed
choices, sharing information about risks and benefits with indi-
viduals and their families.
O B J E C T I V E S
This review aimed to evaluate the effectiveness and safety of dif-
ferent treatment regimens for the treatment of DIOS (complete
and incomplete) in children and adults with CF.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
Randomised controlled trials (RCTs) and quasi-RCTs. We
planned to assess quasi-RCTs on their merit using the Cochrane
risk of bias tool and if satisfied that the groups were similar at
baseline, we planned to include them. We also planned to assess
cross-over trials for possible inclusion on an individual basis. If we
deemed the treatment to alter the condition to the extent that, on
entry to subsequent phases, the participants differed from their
initial state, we would exclude the trial unless we could use data
from the first phase only (see Unit of analysis issues).
Types of participants
Children, young people and adults with CF (diagnosed with con-
firmed sweat test or mutation analysis, or both) who also have a
confirmed diagnosis of complete or incomplete DIOS (diagnosed
clinically or radiologically). We planned to include both pancre-
atic-sufficient and pancreatic-insufficient individuals.
Types of interventions
We planned to compare each type of pharmacological interven-
tion (osmotic laxatives, stimulant laxatives, mucolytics and other
laxative agents) or surgery used for the treatment of DIOS in chil-
dren, young people and adults with CF to each other, to placebo
or to no intervention.
Types of outcome measures
Primary outcomes
1. Time taken from start of treatment until the resolution of
DIOS (diagnosed clinically or radiologically)
2. Treatment failure rate (e.g. clinician-determined need to
change treatment regimen or need for surgical intervention)
Secondary outcomes
1. Recurrence rate of DIOS (diagnosed clinically or
radiologically) after resolution of DIOS (see primary outcome)
2. Adverse effects
i) serious adverse effects of treatment regimens
(including but not limited to rectal bleeding, intestinal
perforation, mucosal erosions, anaphylactic reaction, vomiting
with electrolyte disturbance)
ii) other adverse effects of treatment (e.g. abdominal
distension, soiling, loss of continence or pain)
3. Adherence to treatment (this will help to provide
information about the tolerability of the treatment)
Search methods for identification of studies
We planned to search for all relevant published and unpublished
trials without restrictions on language or publication status.
Electronic searches
The authors identified potentially relevant studies from the
Group’s Cystic Fibrosis Trials Register using the term: distal in-
testinal obstruction syndrome (DIOS).
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of The Cochrane Library),
weekly searches ofMEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major cystic fibrosis con-
ferences: the International Cystic Fibrosis Conference; the Euro-
pean Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for
the register, please see the relevant sections of the Cochrane Cystic
Fibrosis and Genetic Disorders Group’s website.
Date of the most recent search: 24 July 2018.
We searched the following databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library
www.thecochranelibrary.com;
• MEDLINE Ovid (1946 onwards);
• Embase HDAS (Healthcare Databases Advanced Search)
(1974 onwards).
We also searched the following trials registries and other resources:
• US National Institutes of Health Ongoing Trials Register
Clinicaltrials.gov (www.clinicaltrials.gov);
• International Standard Randomised Controlled Trial
Number ( ISRCTN) Registry ( www.isrctn.com );
• World Health Organization International Clinical Trials
Registry Platform ( WHO ICTRP) ( apps.who.int/trialsearch);
• Open Grey ( www.opengrey.eu/).
For details of our search strategies, please see the appendices (
Appendix 2). Date of the most recent search: 10 June 2018.
Searching other resources
We checked the bibliographies of included trials and any relevant
systematic reviews identified for further references to relevant tri-
als.
Data collection and analysis
Selection of studies
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Once we had the complete list of identified references, one author
(JG) checked for duplicates and removed them. Two authors (JG
and FG) reviewed all titles and abstracts and discarded references
which clearly did not meet the inclusion criteria. We planned to
resolve any disagreements by discussion, but if we could not reach
a decision, the third author (WC) would have acted as an external
arbiter to mediate until we could reach a final conclusion. Once
we discarded trials on the basis of title and abstract, we planned
to obtain full copies of the remaining references and screen these
using a standardised screening form customised for this review.
We considered trials in any language and planned to translate them
as necessary. We planned to include trials published as full texts;
if there was only an abstract available, we would include it if it
presented results. If there were no results presented within the
abstract or on any trials registry sites, then we would classify the
trial as ’Awaiting assessment’ until more informationwas available.
Similarly with ongoing trials, if a trial met our inclusion criteria
and quality assessment then we would include it.
We have presented the results of the search using a standardised
flow chart.
Data extraction and management
Two authors (JG and FG) independently performed data extrac-
tion for the included trial. Data extraction is a significant part
of a Cochrane Review, as authors must collect important infor-
mation from each of the included trials and record the data on a
detailed form. We collected data using the data extraction form
on Covidence, an online software program that provides detailed
data extraction forms for Cochrane Reviews (Covidence 2017).
We aimed to collect data on:
• participant characteristics;
• trial characteristics and trial design;
• intervention and comparator;
• outcome data - we will report data for each outcome
separately.
One author (JG) checked the two independently completed data
extraction forms for discrepancies and if there had been any which
we could not resolve by discussion, the third author (WC) would
have arbitrated.
We would have entered the data extracted into Review Manager
software for analysis, but none were available (RevMan 2014).
We planned to report data at up to one week, up to two weeks,
up to one month, up to three months, up to six months and
up to one year. If data had been reported at other time points
we would have considered reporting these too. We planned to
initially carry out a comparison of any osmotic agents, stimulant
laxatives or mucolytics versus placebo or usual treatment with
further subgroup analyses planned as data allowed (see below).
Assessment of risk of bias in included studies
Weused the risk of bias tool as described in theCochrane Handbook
for Systematic Reviews of Interventions to assess the risk of bias
across six domains (sequence generation, allocation concealment,
blinding, incomplete outcome data, selective reporting and other
potential sources of bias) (Higgins 2011).
If the trial described methods of randomisation in the allocation
of participants to their intervention groups, we would assign a
low risk of bias only if the described method of randomisation
was adequate (e.g. computer-generated random number lists). We
also looked for methods of concealment of the allocation sequence
from the researchers, and if we deemed these to be adequate, then
we ranked the trial as having a low risk of bias for this domain.
Examples of an adequate method of concealment may include
the use of opaque sequentially numbered sealed envelopes. Where
these methods were inadequate, we ranked the trial as being at
a high risk and where it was unclear from the description given,
then we ranked it as having an unclear risk of bias.
Similarly for blinding, the trial should state that participants and
personnel were blinded, in order to have a low risk of bias for this
domain. We also looked for the blinding of outcome assessors,
which should be specifically mentioned for the rank of low risk of
bias.
For the domain of incomplete outcome data, we planned to extract
information on missing data and how the investigators recorded
participant withdrawals and loss to follow-up. We also planned to
look at whether missing data were equally distributed between the
intervention and control groups. If the review authors agree that
missing data have been accounted for adequately, then we would
judge the trial to be at a low risk of bias. We planned to record
the trial as having a high risk of bias if the missing data had not
been reported adequately and would have recorded it as having
an unclear risk of bias if we were unable to see how the missing
data had been reported. We planned to assess each included trial
to determine whether the investigators used an intention-to-treat
(ITT) analysis and again, once we had reached an agreement, we
would rank the trials as being at a high, low or unclear risk of
bias. If a trial had a high risk of bias for missing data but a low
risk of bias for ITT analysis or vice versa, we would look into
more detail at the data to make a final judgement. This would
include looking at the proportion of randomised participants who
have been analysed as ITT and howmany individuals dropped out
relative to the total number of participants in the trial. If these data
were high, then the overall risk of bias for incomplete outcome
data would be high.
If the trial investigators reported all outcomes in the paper, we
planned to record a low risk of bias from selective reporting. If
the paper stated that investigators measured outcomes, but they
did not report the results of these, the review authors would rank
the paper as being at high risk. If it was unclear to the us whether
the trial reports all outcomes measured, then we planned to state
this and rank it as unclear for this domain. We also planned to
search for trial protocols to be able to assess outcome reporting. If
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we could not locate the protocol, we planned to assess outcome
reporting based on a comparison between the methods section of
the full published paper and the results section.
We planned to look for any other potential sources of bias in the
included trials and record what we find. If we could not find any
other source of bias, then we planned to rank the trial as having a
low risk for this domain and high risk if the opposite is true.
We presented the results of the risk of bias assessment both indi-
vidually and in a summary table.
Measures of treatment effect
For dichotomous data (adverse effects, treatment failure, recur-
rence and adherence), we planned to calculate a pooled estimate
of the treatment effects for each outcome across trials using risk
ratio (RR) and 95% confidence intervals (CIs) where appropriate.
For continuous data, we planned to record the mean change and
standard deviation (SD) from baseline for each group. We in-
tended to calculate a pooled estimate of treatment effect using
the mean difference (MD) and 95% CIs. Where trials use differ-
ent units of measurement or measurement scales for reporting the
same outcome, we planned to use the standardised MD (SMD) to
report the results. Where trials only report only a pre-intervention
mean (SD) and post-intervention mean (SD) then we intended
to calculate the mean change but not the SD of the change. We
planned to report these results narratively.
For time-to-event data (time to resolution of DIOS) we intended
to express the intervention effect as a hazard ratio (HR) with 95%
CIs using the generic inverse variance method. It may be that
time taken to resolution of DIOS is reported as continuous data
(rather than time-to-event data) in some trials. If this is the case,
we planned to seek advice from Cochrane, but would analyse the
results according to how the majority of included trials present the
data, so that we could obtain an accurate estimate of treatment
effect.
Where end-points are semantically different but report to similar
outcomes thenwe planned to group outcomes. Thus, synonymous
terms were considered jointly. We considered:
• abdominal distension to be synonymous with bloating,
swelling, gaseous distension;
• pain to be synonymous with discomfort or ache;
• vomiting to be synonymous with emesis; and
• constipation to be synonymous with straining at stool or
dyschezia.
Unit of analysis issues
We assessed any trials using a cross-over design to establish how
much data we could include in the analysis. We included the trial
if the authors had taken account of the cross-over design in the
analysis, any carry-over effect (i.e. included a washout period for
the intervention) and within-person differences. Where the origi-
nal authors had not analysed the data appropriately, we planned to
include data from the first phase of the cross-over trial as if it were
a parallel design; although the advantage of the cross-over design
(using participants as their own controls) would be lost (Elbourne
2002).
If we found trials which were multi-arm they would possibly fall
intomore thanone comparison. In such cases, where the two active
treatment arms are different types of laxative regimen, e.g. macro-
gol 3350 versus lactulose and senna versus placebo, we planned to
analyse each treatment arm separately against placebo and where
appropriate included in ameta-analysis. If the two active treatment
arms were of the same type of laxative (e.g. softening agents), but
employ a different laxative or dose, we intended to combine them
against the placebo arm to look at the effect of the type of laxative
rather than an individual drug. When analysing multi-arm stud-
ies, it would also be sensible to split the placebo group in order to
avoid active treatments being compared to the same individuals.
If there was heterogeneity between trials looking at different types
of laxative regimen, we planned to carry out a subgroup analysis
to look at the effect of individual drugs (see Subgroup analysis and
investigation of heterogeneity).
Dealing with missing data
We planned to request additional data from the trial author(s) if
there were insufficient data in the published paper or uncertainty
about data we are able to extract from the included trials. We
planned to undertake an intention-to-treat (ITT) analyses wher-
ever possible throughout the review.
We also planned to assess the extent to which trial authors had
employed an ITT analysis and we planned to report the numbers
of participants who dropped out of each arm of the trial, where
possible.
Where data are incomplete but partially available, we intended to
use the last available measurement.
Assessment of heterogeneity
Where there are trials reporting the same outcomes which we were
able to include in a meta-analysis, we planned to assess the level
of heterogeneity using the I² statistic. We also planned to look at
the overlap of the CIs on the forest plots to gauge the significance
of the I² value.
We planned to base our definitions of different levels of hetero-
geneity on the levels described in the Cochrane Handbook for Sys-
tematic Reviews of Interventions:
• low (might not be important) = 0% to 40%;
• moderate = 30% to 60%;
• substantial = 50% to 90%; and
• considerable = 75% to 100%.
The Cochrane Handbook for Systematic Reviews of Interventions
states that this is a rough guide because the importance of incon-
sistency depends on several factors (Deeks 2011).
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Assessment of reporting biases
Where we were able to include at least 10 trials, we planned to
generate a funnel plot to attempt to identify any publication bias
in the included trials (Sterne 2011). We would also attempt to
identify any selective reporting in the included publications, by
comparing the trial protocols with the final papers and by care-
ful examination of the trial publications and consideration of re-
porting of both positive and negative effects of the intervention.
Where trial protocols were not available, we planned to compare
the outcomes reported in the results section against the methods
section of the paper. We planned to extract information on the
sponsors, sources of funding and competing interests of the au-
thors to determine the role of external bias being introduced. To
minimise publication bias, we planned to contact pharmaceutical
companies for unpublished data; we searched trial registries (as
detailed above).
Data synthesis
Where we were able to combine trials in a meta-analysis, we
planned to use the data from the selected trials to generate for-
est plots using the Review Manager software (RevMan 2014). We
planned to carry out separate meta-analyses for different groups
of laxative agents (e.g. osmotic laxatives, stimulant laxatives and
mucolytics and those with a combined mechanism of action) ver-
sus placebo, usual treatment or each other. We intended to exam-
ine the level of heterogeneity to determine which type of analy-
sis model to use. If there was low heterogeneity (less than 40%)
then we planned to use a fixed-effect model and if the I² statistic
was greater than 40% then we would use a random-effects model
to summarize the data. However, it is important to note that as
the random-effects model allows for heterogeneity, the CI for the
pooled estimate will be wider and therefore, less precise. If het-
erogeneity was considerable (I² over 75%), we planned to report
results narratively as it would not be appropriate in these cases to
combine results in a meta-analysis.
Subgroup analysis and investigation of heterogeneity
If there was greater than 40% heterogeneity in the included trials,
we planned to undertake the following subgroup analyses:
• comparison of individual treatment agents (e.g. lactulose
versus senna) or combinations or agents (e.g. lactulose plus senna
versus diatrizoate);
• children (under 18 years of age) versus adults;
• route of administration (e.g. oral, via nasogastric tube, via
gastrostomy or rectally).
Sensitivity analysis
If we had performed a meta-analysis, we planned to carry out sen-
sitivity analyses to look at the effect of the risk of bias findings. We
intended to look at the effect of adding in and taking out trials
with a high risk of bias. For example, we would include the high
risk of bias trials in the main meta-analysis, but would look at the
effect of excluding those trials whose eligibility criteria was ques-
tionable (e.g. quasi-RCTs with unclear baseline characteristics) or
those with a high risk of bias (e.g. high degree of missing data
not accounted for) in the sensitivity analysis in order to examine
their overall effects on the review. We also planned to attempt to
examine the effect of cross-over trials on the results by carrying
out a sensitivity analysis to include and exclude them.
Summary of findings tables
We reported summary of findings information; we planned to
present a separate table for each treatment comparison,where there
was at least one trial assessing our chosen outcomes comparing
laxative agents versus control, placebo or alternate regimens for the
outcomes: time to resolution of DIOS; treatment failure; recur-
rence of DIOS; adverse effects; and adherence. Thus we currently
present a single table.
For each outcome we planned to report the illustrative risk with
and without the intervention, magnitude of effect (RR or MD),
numbers of trials and participants addressing each outcome and a
grade of the overall quality of the body of evidence using theGrad-
ing of Recommendations Assessment, Development and Evalua-
tion (GRADE) with comments (Schünemann 2011).
R E S U L T S
Description of studies
Results of the search
There were 2631 references retrieved after electronic searches. Of
these, eight references (seven trials) were considered eligible after
screening. After full text screening, one trial was included in the
review. Details of the included trial and reasons for excluding the
remaining six trials can be found below. The flow diagram can be
found in Figure 1.
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Figure 1. Study flow diagram
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Included studies
There was one trial included in the review which was only avail-
able as an abstract (Dalzell 1993). We attempted to contact the
authors, who informed us that there was no full text version of the
trial available. It was a single-centre, double-blind, randomised,
cross-over trial that took place at the Royal Liverpool Children’s
Hospital, Alder Hey in the UK. The trial included 20 participants
(16 female) with an age range of 7.1 years to 23.2 years, giving a
mean age of 13.1 years. Participants were required to have a diag-
nosis of chronic DIOS to be included in the trial.
Participants were randomly given either high-dose or low-dose
pancreatic enzymes for six months each. Trial investigators mea-
sured the difference in acute episodes of DIOS, presence of an
abdominal mass and abdominal pain. Other outcomes measured
in the trial included the coefficient for fat absorption and weight
gain.
More details of the included trial can be found in the
Characteristics of included studies table.
Excluded studies
Please see the Characteristics of excluded studies table for more
information.
Six trials were excluded in total. Five of these were excluded be-
cause the indication was wrong, i.e. N-acetylcysteine was not used
to treat DIOS. In four trials N-acetylcysteine was used as an in-
tervention for CF lung disease (Baran 1980; Dietzsch 1980; Gotz
1980; Howatt 1966). In one trial N-acetylcysteine was used to im-
prove malabsorption in CF (Mitchell 1981). The remaining trial
excluded because the intervention was used for preventing DIOS
rather than treating DIOS (Koletzko 1990).
Risk of bias in included studies
The general risk of bias of the included trial was unclear, as there
was not enough information to judge most of the domains. For
more information on the risk of bias, please see the Characteristics
of included studies table and the risk of bias summary (Figure 2).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The trial was described as randomised, but the method of how
this was done was unclear. There was no information in the trial
about whether the allocation to high-dose or low-dose pancreatic
enzymes was concealed; this was therefore also judged as having
an unclear risk of bias.
Blinding
The trial, which was only published as a conference abstract, was
described as double-blinded, so we judged this to have a low risk
of bias. We accepted this description because it is unlikely that the
authors would have gone into detail on exactly who was blinded
and how it was done (e.g. making the two doses of PERT look,
smell and taste identical) in the abstract. However, we also recog-
nise that these details should be discussed fully in the text of the
trial. Detection bias was low risk for two outcomes as these were
objective measures:the episodes of acute DIOS and presence of an
abdominal mass. However, there was not information about the
blinding of outcome assessors for the outcome of abdominal pain.
We judged this as having an unclear risk of bias because pain is a
subjective outcome.
Incomplete outcome data
The trial did not describe any withdrawal of participants, nor
whether there was an intention-to-treat analysis. There was insuf-
ficient information to judge the risk of bias in this domain, there-
fore, we ranked it as unclear.
Selective reporting
As the trial was only available as an abstract (and there was no
protocol available), we could not compare the outcomes in the
methods with those in the results section. There was insufficient
information to judge whether there was selective reporting, so we
ranked it as having an unclear risk of bias for this domain.
Other potential sources of bias
Therewas insufficient information in the abstract to judgewhether
there was a washout period between the first and second phase of
the trial. No other potential sources of bias were identified.
Effects of interventions
See: Summary of findings for the main comparison
Please see the summary of findings table (Summary of findings for
the main comparison).
As therewas only one trial in this review,wewere unable to perform
meta-analysis of the data. Furthermore, as the included trial was
only available as an abstract, no data could be presented in the
results, although three outcomes were relevant to our review. We
tried to contact the authors for a full-text copy of the review, but
we were unsuccessful.
Primary outcomes
1. Time taken from start of treatment until the resolution of
DIOS
The included trial did not report this outcome measure.
2. Treatment failure rate
The included trial did not report this outcome measure.
Secondary outcomes
1. Recurrence rate of DIOS after resolution of DIOS
The included trial reported the number of episodes of acute DIOS
during the 12-month trial period. It stated that there was no dif-
ference in episodes between high-dose and low-dose pancreatic
enzymes.
2. Adverse effects
a. serious adverse effects of treatment regimens
The included trial did not report this outcome measure.
b. other adverse effects of treatment
The included trial reported the adverse effects abdominal mass
and abdominal pain. It stated that there was no difference in either
event between high-dose or low-dose pancreatic enzymes. Numer-
ical data were not available for these outcomes.
3. Adherence to treatment
The included trial did not report this outcome measure.
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D I S C U S S I O N
Summary of main results
As there was one included trial in this review, we could not perform
a meta-analysis of data. The trial was only available as an abstract
and did not provide numerical data for any of our outcomes.
The trial did not address our primary outcomes (time until the
resolution of DIOS and treatment failure rate) but addressed two
of our secondary outcomes (episodes of acute DIOS and adverse
effects (abdominal mass and abdominal pain)). The authors stated
that there were no differences in the episodes of acute DIOS or in
the adverse effects between the two treatment arms, but did not
provide numerical data to support this.
A summary of the evidence from the single comparison in this re-
view (high-dose pancreatic enzymes compared with low-dose pan-
creatic enzymes) is presented in the tables (Summary of findings
for the main comparison).
Overall completeness and applicability of
evidence
In this review, there was an absence of assessment regarding the ef-
ficacy and safety of various laxative agents for treating DIOS. The
only included trial failed to address our review objective or our
primary outcomes, therefore, the overall completeness and appli-
cability of this evidence to the wider CF population is extremely
limited.
Quality of the evidence
The lack of included trials does not allow a robust conclusion
regarding the objective of this review. The only included trial was
small (comprising 20 participants) adding to the imprecision of
the results. The participants also had a limited age range, between
7.1 and 23.2 years. This restricts the main review objective to a
small group of participants and thus contributes to the indirectness
of the evidence in the review. Furthermore, although the trial was
a randomised, double-blind and cross-over in design, it failed to
address our primary outcomes and twoof our secondary outcomes.
The included trial also only compared low-dose to high-dose pan-
creatic enzyme therapy, but specific dose levels were not described.
There were also no other types of laxatives (osmotic, stimulant
or bowel cleansing agents) assessed for the treatment of DIOS,
which contributes to the indirectness of the evidence. Only the
abstract of this trial was available, so we are unable to comment on
the consistency or inconsistency of the results, or whether there
was any selective reporting. Other areas of potential bias such as
allocation or incomplete outcome data were also unclear.
Potential biases in the review process
We conducted comprehensive electronic searches on medical
databases and registries in order to identify suitable trials for this
review, therefore reducing bias. However, since the only RCT on
this topic took place in 1992 and to our knowledge, there have
been none since then that matched our inclusion criteria, it may
suggest a degree of publication bias. Furthermore, we were unable
to obtain a full-text version of the included trial, even after con-
tacting one of the authors, meaning that we were unable to access
the relevant data in the trial. This may also indicate that there was
publication bias.
Within the review process, two authors independently screened
and assessed trials for eligibility, as well as assessing for risk of
bias. A third author acted as external arbiter in order to solve any
disagreements. This process reduced the risk of bias.
Agreements and disagreements with other
studies or reviews
As far as we are aware, there have not been any other systematic
reviews or RCTs (other than the included trial in this review)
comparing interventions for the treatment of DIOS. It is generally
accepted that good adherence to PERT can reduce constipation
and gastrointestinal symptoms in CF, but there is no high-quality
evidence that assesses the use of PERT for the treatment of DIOS.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Despite the use of various laxative agents for the treatment of
distal intestinal obstruction syndrome (DIOS) in clinical practice,
this review concludes that there is no consensus or evidence-base
regarding the efficacy and safety of current interventions used to
treat DIOS. There is no high-quality evidence that compares the
use of pancreatic enzyme replacement therapy (PERT) or any other
laxative regimen for treating DIOS.
Implications for research
This review has highlighted that there is a severe lack of evidence
for the treatment of DIOS in children and adults with cystic fibro-
sis (CF). Therefore, there is a need for further randomised con-
trolled trials with much larger numbers of participants to be car-
ried out, comparing the current laxatives used in clinical practice
(e.g. osmotic laxatives, stimulants, mucolytics and bowel cleans-
ing agents) at any dose, with placebo, no treatment or with other
laxatives. However, one must consider the ethical implications of
using a placebo to treat DIOS, as it is a serious and potentially
dangerous condition, especially if the individual experiences com-
plete obstruction.
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Future trials should include a range of participants including chil-
dren and adults, as DIOS occurs in both of these groups. Future
research should also address important outcomes for the treatment
of DIOS, as highlighted in this review. These outcomes may in-
clude the time taken from the start of the treatment until the reso-
lution ofDIOS, recurrence ofDIOS after successful treatment and
adverse effects from treatments. In addition, future trials should
include a follow-up period in order to identify participants who
may experience a recurrence of DIOS. They should also be de-
tailed in their description of the methodology used, to ensure that
an accurate assessment of the risk of bias can be carried out.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dalzell 1993
Methods Randomised double-blind trial.
Cross-over design.
Single centre (UK).
Participants 20 participants (16 female) with mean age of 13.1 years (range 7.1 to 23.2) with CF and
a diagnosis of chronic DIOS
Interventions High-dose pancreatic enzymes compared to low-dose pancreatic enzymes for the treat-
ment of chronic DIOS
Outcomes • co-efficient for fat absorption for participants
• weight gain
• episodes of acute DIOS
• abdominal mass
• abdominal pain
Notes There was no information available regarding the source of funding for the trial. No
declarations of the interest from the primary researchers were stated in the trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not enough information to make a judge-
ment onwhether there was true random se-
quence generation, although the trial stated
that the participants were randomised
Allocation concealment (selection bias) Unclear risk Not enough information to make a judge-
ment on whether there was allocation con-
cealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated that this was a “double-blind” trial.
Blinding of outcome assessment (detection
bias)
Episodes of acute DIOS
Low risk This is an objective measurement, so the
blinding of outcome assessors is not impor-
tant
Blinding of outcome assessment (detection
bias)
Abdominal mass
Low risk This is an objective measurement, so the
blinding of outcome assessors is not impor-
tant
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Dalzell 1993 (Continued)
Blinding of outcome assessment (detection
bias)
Abdominal pain
Unclear risk This is a subjective measurement, so the
blinding of outcome assessors is important.
There is not enough information to make a
judgement on whether there was blinding
of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not enough information to make a judge-
ment onwhether therewas incomplete out-
come data. No intention-to-treat analysis
was described, nor was there any informa-
tion on withdrawal of participants
Selective reporting (reporting bias) Unclear risk Not enough information to make a judge-
ment on whether there was selective report-
ing. There was no protocol available and
the trial was only available as an abstract
Other bias Unclear risk Therewas insufficient information to judge
whether there was a washout period be-
tween the first and second phase of the trial.
Therewas not enough information tomake
a judgement on whether there were other
forms of bias
CF: cystic fibrosis
DIOS: distal intestinal obstruction syndrome
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baran 1980 Wrong indication: N-acetylcysteine was used to treat respiratory complications of CF rather than DIOS
Dietzsch 1980 Wrong indication: N-acetylcysteine was used to treat respiratory complications of CF rather than DIOS
Gotz 1980 Wrong indication: N-acetylcysteine was used to treat respiratory complications of CF rather than DIOS
Howatt 1966 Wrong indication: N-acetylcysteine was used to treat respiratory complications of CF rather than DIOS
Koletzko 1990 Wrong intervention: trial to assess interventions for preventing DIOS rather than treating it
Mitchell 1981 Wrong indication: N-acetylcysteine was used to improve malabsorption in CF rather than for treating DIOS
CF: cystic fibrosis
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DIOS: distal intestinal obstruction syndrome
A P P E N D I C E S
Appendix 1. Glossary of terms
Term Explanation
anaphylactic reaction a life-threatening allergic reaction that may result in severe respiratory and/or cardiovascular
distress and skin reactions; it is a medical emergency
autosomal recessive a form of genetic inheritance in which two copies of a gene are required for a characteristic
or condition to be carried to the offspring
caecum this is the beginning of the large intestine and is connected to the end of the small intestine
(known as the terminal ileum); it is located in the right lower quadrant of the abdomen
dyschezia painful defecation
emesis vomiting
intestinal perforation a hole that forms in the intestine causing its contents to leak into the abdomen; this is a
surgical emergency
mucosal erosions the wearing away or abrasion of a surface or lining, e.g. gastric erosions relates to abrasion of
the stomach lining
synonymous terms or words that have the same meaning e.g. small is synonymous with petite
terminal ileum the end of the small intestine, it is connected to the caecum (see above)
vomiting with electrolyte disturbance severe vomiting that leads to important electrolytes e.g. sodium, potassium, calcium being
lost from the body
For definitions of statistical and methodological Cochrane terms (e.g. cross-over trial, funnel plot, forest plot, heterogeneity, quasi-
randomised controlled trial) please see the Cochrane Community Glossary.
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Appendix 2. Search strategies
Database/Resource Strategy
Cochrane Central Register of Controlled Trials (CENTRAL) #1 Cystic Fibrosis [MeSH descriptor]
#2 cystic fibrosis:ti,ab
#3 fibrocystic near/10 disease near/10 pancreas
#4 mucoviscidos*:ti,ab
#5 cystic* near/10 fibros*:ti,ab
#6 #1 or #2 or #3 or #4 or #5
#7 distal intestinal obstruction syndrome*:ti,ab
#8 dios or mie:ti,ab
#9 Intestinal Obstruction [MeSH descriptor]
#10 meconium ileus equivalent:ti,ab
#11 faecal near/3 (obstruction or impact*):ti,ab
#12 Constipation [MeSH descriptor]
#13 constipat*:ti,ab
#14 laxative*:ti,ab
#15 Laxatives [MeSH descriptor]
#16 lactulose:ti,ab
#17 Lactulose [MeSH descriptor]
#18 (macrogol or polyethylene glycol*):ti,ab
#19 Polyethylene Glycols [MeSH descriptor]
#20 movicol:ti,ab
#21 klean*:ti,ab
#22 diatriozate:ti,ab
#23 gastrografin:ti,ab
#24 sennati:ti,ab
#25 docusate:ti,ab
#26 bicosulfate:ti,ab
#27 acetylcysteine or fibrol:ti,ab
#28 parvolex:ti,ab
#29 fibre:ti,ab
#30 picosulphate:ti,ab
#31 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #
16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25
or #26 or #27 or #28 or #29 #30
#32 #6 and #31
MEDLINE Ovid (1946 onwards) 1. Cystic Fibrosis/
2. cystic fibrosis.tw.
3. (fibrocystic adj10 disease adj10 pancreas).tw.
4. mucoviscidos$.tw.
5. (cystic$ adj10 fibros$).tw.
6. 1 or 2 or 3 or 4 or 5
7. “distal intestinal obstruction syndrome*”.tw.
8. (dios or mie).tw.
9. Intestinal Obstruction/
10. meconium ileus equivalent.tw.
11. (faecal adj3 (obstruction or impact*)).tw.
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(Continued)
12. Constipation/
13. “constipat*”.tw.
14. “laxative*”.tw.
15. Laxatives/
16. lactulose.tw. or Lactulose/
17. (macrogol or polyethylene glycol*).tw. or Polyethylene Glycols/
18. movicol.tw.
19. klean*.tw.
20. diatriozate.tw.
21. gastrografin.tw.
22. senna.tw.
23. docusate.tw.
24. bicosulfate.tw.
25. acetylcysteine or fibrol.tw.
26. parvolex.tw.
27. fibre.tw.
28. picosulphate.tw.
29. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. 6 and 29
Embase Ovid (1974 onwards) 1. CYSTIC FIBROSIS/
2. cystic fibrosis.tw.
3. (fibrocystic adj10 disease adj10 pancreas).tw.
4. mucoviscidos$.tw.
5. (cystic$ adj10 fibros$).tw.
6. 1 or 2 or 3 or 4 or 5
7. “distal intestinal obstruction syndrome*”.tw.
8. (dios or mie).tw.
9. INTESTINE OBSTRUCTION/
10. meconium ileus equivalent.tw.
11. (faecal adj3 (obstruction or impact*)).tw.
12. CONSTIPATION/
13. “constipat*”.tw.
14. “laxative*”.tw.
15. LAXATIVE/
16. lactulose.tw. or LACTULOSE/
17. (macrogol or polyethylene glycol*).mp,hw.
18. movicol.tw.
19. klean*.tw.
20. diatriozate.tw.
21. gastrografin.tw.
22. senna.tw.
23. docusate.tw.
24. bicosulfate.tw.
25. acetylcysteine or fibrol.tw.
26. parvolex.tw.
27. fibre.tw.
28. picosulphate.tw.
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(Continued)
29. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. 6 and 29
Clinicaltrials.gov ADVANCED SEARCH
Search 1
Search terms: laxative OR laxatives OR lactulose OR macrogol OR
polyethyleneORmovicol OR klean OR diatriozate OR gastrografin
OR senna OR docusate OR bicosulfate OR acetylcysteine OR fibrol
OR parvolex OR picosulphate OR fibre
Study type: Interventional Studies
Conditions: cystic fibrosis
Search 2
Search terms: intestinal OR DIOS OR constipation OR constipated
OR faecal OR meconium
Study type: Interventional Studies
Conditions: cystic fibrosis
ISRCTN Registry ADVANCED SEARCH
Condition: cystic fibrosis
WHO ICTRP BASIC SEARCHES
Search 1: cystic fibrosis AND intestinal
Search 2: cystic fibrosis AND constipation
Search 3: cystic fibrosis AND faecal
Search 4: cystic fibrosis AND meconium
Search 5: mucoviscidose
ADVANCED SEARCH
Condition: cystic fibrosis
Intervention: laxative OR laxatives OR lactulose OR macrogol OR
polyethyleneORmovicol OR klean OR diatriozate OR gastrografin
OR senna OR docusate OR bicosulfate OR acetylcysteine OR fibrol
OR parvolex OR picosulphate OR fibre
Recruitment Status: All
Open Grey (cystic fibrosis OR cf OR mucoviscidos*) AND (intestin* OR con-
stipat* OR faecal OR meconium OR laxative* OR lactulose OR
macrogol OR polyethylene OR movicol OR klean* OR diatriozate
OR gastrografin OR senna OR docusate OR bicosulfate OR acetyl-
cysteine OR fibrol OR parvolex OR picosulphate OR fibre)
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C O N T R I B U T I O N S O F A U T H O R S
Roles and responsibilities
TASK WHO WILL UNDERTAKE THE TASK?
Protocol stage: draft the protocol JG & FG
Review stage: select which trials to include (2 + 1 arbiter) JG, FG &WC
Review stage: extract data from trials (2 people) JG & FG
Review stage: enter data into RevMan JG
Review stage: carry out the analysis JG, FG &WC
Review stage: interpret the analysis JG, FG &WC
Review stage: draft the final review JG & FG
Update stage: update the review FG
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